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ABSTRACT: This communication shows that the con-
cept of Brownian trapping with drift can be applied to
improve quantitative molecular measurements. It has the
potential to combine the robustness of end-point spatially
resolved readouts, the ultrasensitivity of digital single-
molecule measurements, and the large dynamic range of
qPCR; furthermore, at low concentrations of analytes, it
can provide a direct comparison of the signals arising from
the analyte and from the background. It relies on the
ﬁnding that molecules simultaneously diﬀusing, drifting
(via slow ﬂow), and binding to an array of nonsaturable
surface traps have an exponentially decreasing probability
of escaping the traps over time and therefore give rise to
an exponentially decaying distribution of trapped mole-
cules in space. This concept was tested with enzyme and
protein measurements in a microﬂuidic device.
Digital single-molecule measurements,1 such as digital PCR(dPCR)2 and digital immunoassays,3 compartmentalize
molecules of the target analyte and perform a detection reaction
providing an “on” or “oﬀ” signal for each compartment (digital
unit). Analyte concentration is then quantiﬁed by counting the
signals and using a Poisson distribution. This methodology has
been used in a wide range of applications to detect nucleic acids
and proteins with ultrasensitivity.4
One limitation of digital measurements is that the dynamic
range (i.e., the range between the lowest and highest
concentrations in a sample that can be measured) is limited by
the number of digital units in the assay. Quantitative real-time
PCR (qPCR) has a much wider dynamic range because input
concentration is calculated as an exponential function of the
qPCR output; however, this method is less convenient than an
end-point measurement. Dynamic range in dPCR can be
increased by introducing very large numbers of digital units
(compartments)5 or using digital units of multiple sizes,6 which
increases the dynamic range by more than ∼100-fold. However,
the multivolume strategy is not as eﬀective for digital
immunoassays that lack the exponential ampliﬁcation of PCR.
One strategy to improve dynamic range for digital immunoassays
involves combining the digital readout with the analog readout,
which has increased the dynamic range from 2.5 logs to 4.1 logs.7
Such improvement is desired, for example, in assays for the
biomarker glial ﬁbrillary acidic protein (GFAP) in traumatic
brain injury.8
Our goal was to test whether it would be possible to combine
into a single measurement (i) the high sensitivity of digital assays,
in which individual molecules give rise to on/oﬀ signals, (ii) the
broad dynamic range (∼108) characteristic of a technique like
qPCR, in which large changes in the input concentration give rise
to logarithmically smaller changes in the output (Cq); in other
words, input concentration is calculated as an exponential
function of the output; and (iii) a readout in which the input
number of molecules is quantiﬁed by an end-point spatial signal,
which is more robust than the temporal signal from kinetic real
time assays.9
Here, we tested whether our goal could be reached by
implementing the concept of Brownian trapping with drift10 in a
microﬂuidic device (Figure 1). In Brownian trapping, target
objects move by diﬀusion and are captured by traps of radius ρ
and trap density v. When Brownian trapping is combined with
directional drift U of the target objects,10 the probability of a
target object eluding the traps, P(t;U,v,ρ), decays exponentially at
long times with decay rate λ(U,v,ρ), a function of U,v and ρ (eq
1).10c
ρ λ ρ≈ −P t U v U v t( ; , , ) exp( ( , , ) ) (1)
This exponential decay only occurs when traps are not
saturated by the targets during the experiment. This phenom-
enon has been analyzed mathematically in the context of charge
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Figure 1. Conceptual schematic of a digital measurement using
Brownian trapping with drift. This concept aims to combine the
ultrasensitivity of digital detection (shown in blue) with the broad
dynamic range inherent in real-time PCR assays, in which large changes
in the input concentration give rise to logarithmically smaller changes in
the output (shown in red).
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carriers in semiconductors,10a diﬀusion-controlled reactions in
the presence of a biasing ﬁeld,10d and photoluminescence in the
presence of electrical bias,10b but has not been applied to
molecular analyses.
To test Brownian trapping in a digital immunoassay (Figure
1), we envisioned the target object was a protein analyte
molecule, and the traps were areas containing a capture reagent,
such as an antibody. Traps were distributed on the channel
surface, conﬁgured to act as digital units and grouped into regions
(Figure 2). We envisioned introducing drift using a gentle
advective ﬂow of solution through the microﬂuidic channel.
Under these conditions, each trap provides a digital on/oﬀ
readout (Figure 2). At low concentrations, we hypothesized that
most analyte molecules would be trapped at the beginning of the
channel and concentration could be estimated using the
conventional Poisson statistics of digital immunoassays.3c
However, at high concentrations, we hypothesized that analyte
concentration could be estimated using a spatial analogue of eq 1
(see Supporting Information S1).
Our experimental design (Figure 2) satisﬁed four criteria
arising from the concept of Brownian trapping with drift10 (we
have not optimized experimental parameters, instead choosing
one experimentally convenient combination; see Supporting
Information). (i) Drift should dominate over diﬀusion of the
protein target (diﬀusion coeﬃcient D ≈ 10−11 m2/s) along the
ﬂow direction x (here, Pećlet number Pex = UL/D ≈ 103), with
each region suﬃciently long (L ≈ 10−3 m) and ﬂow suﬃciently
high (U ≈ 10−5 m/s). Under these conditions, the exponential
decay over time (eq 1) would be manifested as an exponential
decay over space (Figure 1), eﬀectively converting temporal
distribution into spatial distribution. (ii) At the same time, ﬂow
should be slow enough that diﬀusion of the protein from the top
to the bottom of the channel (H) is not slower than ﬂow over one
region (Pez = (U/L)/(D/H
2) ≈ 2.5); (iii) each trap should have
high binding capacity so it is not saturated by the targets during
the experiment. Beads used for digital immunoassays3,4a,c,d satisfy
this criterion. This criterion has not been met previously in
innovative quantiﬁcation approaches that ﬂow a sample through
a microﬂuidic channel to generate a density gradient on the
channel surface.11 In such experiments, the protein signal
decayed linearly over channel length instead of exponentially.
(iv) TheDamköhler numberDa≈ kon[Ab]L/U, (estimated to be
∼1, [Ab] is the concentration of the capture reagent) should be
close to or greater than 1 to enable rapid capture of the target
molecules once they diﬀuse to the traps.
We tested this concept experimentally using a glass SlipChip
device12 (Figure 2B), which contained 10 parallel arrays created
by dry-etching with C4F8, each containing 540,000 microwells
grouped into regions. Each well was loaded with a single bead
coated with a capture antibody. We took advantage of the relative
movement of the two plates of the SlipChip to achieve uniform
and near-complete bead loading. As the sample passed over the
wells, the protein targets were trapped on the beads, rapidly
depleting the target analyte from the ﬂowing solution.
We ﬁrst used a simple model system with biotin-modiﬁed β-
galactosidase as the target analyte (3 μL samples in a range of
concentrations) and streptavidin-coated beads as the capture
agents. First, the enzyme solution was ﬂown over the beads
through the channel at a velocity of 17 μm/s for 1 h. Then a
solution of ﬂuorogenic substrate resoruﬁn β-D-galactopyranoside
(RGP) was injected into the channel, immediately followed by a
ﬂow of FC40 to compartmentalize the beads in the microwells.
Analyte concentration was estimated using the fraction of beads
that captured at least one molecule (positive fraction of
beads)3,4a,c,d (Figure 3A). Analyte molecules were preferentially
captured in the upstream regions, so low analyte concentrations
were quantiﬁed by the positive fraction of wells located in the ﬁrst
capture region (Figure 3B). We calculated the limit of detection
(LOD) from three times the standard deviation of the
experimentally measured background signal to be 9 aM. At
higher concentrations, as is established,7 we used a fraction of 0.8
as the practical upper limit, corresponding to 20 fM (Figure 3B).
At high analyte concentrations, beads in the upstream regions
contained many analyte molecules, precluding end-point digital
quantiﬁcation using those regions (we emphasize that beads,
which could bind ∼105 analyte molecules, were not expected to
be fully saturated with analyte under those conditions). Analyte
molecules were also captured in the downstream regions. As
predicted, we observed that exponentially increasing analyte
concentration gave rise to an approximately linear shift in the
region where the capture curve crossed a threshold value of
positive fraction (Figure 3A,C,D). We refer to this region as Rq
(region of quantiﬁcation), analogous to Cq used in qPCR; its
position depends on the value of the chosen threshold. Using a
low threshold of 0.07 positive fraction (Figure 3C) provided a
dynamic range that overlapped well with the digital calibration
curve (Figure 3B) while extending it by ∼102 (above 1 pM).
Using a high threshold of 0.8 positive fraction (Figure 3D)
further extended the dynamic range above 0.3 nM. The
combined dynamic range was ∼4 × 107-fold, with a sensitivity
of ∼20 molecules in 3 μL.
Figure 2. Experimental design to test the concept of digital
measurements based on Brownian trapping with advective drift. (A)
Schematic of the design, which features a shallow channel (50 μm) on
top of an array of microwells. A bead (orange) coated with a capture
reagent (e.g., an antibody), is placed in each microwell. The channel
guides the ﬂow of the sample over the microwells, and target molecules
(blue) are captured by the beads. After labeling, the microwells are
compartmentalized by ﬂuorocarbon for digital readout. (B) A
photograph of an assembled device with 10 parallel arrays. (C) A
ﬂuorescent image of the digital readout.
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For comparison, in an identical SlipChip device we performed
a standard digital protein assay in which the whole solution was
injected into the device rapidly and kept stationary during a 1 h
incubation, followed by detection as described above. The
calculated dynamic range in this stationary assay ranged from
0.02 fM to 0.5 pM, demonstrating a range of ∼20,000-fold, and a
sensitivity of ∼30 molecules (Figure 3E). Therefore, the digital
measurement based on Brownian trapping with drift showed
similar sensitivity but a more than 1000-fold improvement in
dynamic range relative to the stationary digital assay in the same
device.
We then tested how this approach performs in a more
complex, clinically relevant immunoassay for a human protein
target, TNF-α in a 25% serum. To streamline the multistep
ELISA protocol, we adopted a cartridge-with-spacers approach in
which all reagents were loaded into a cartridge as plugs separated
by FC40 ﬂuorocarbon and air, then delivered into the channel13
(Figure S3, Supporting Information). We performed calibrations
with 8 μL samples containing known TNF-α concentrations in
buﬀered 25% bovine serum. The captured TNF-α molecules
were then incubated with 6.5 nM biotinylated detection antibody
for 1 h, followed by a 0.5 h incubation with 400 pM
streptravidin−galactosidase conjugate and compartmentaliza-
tion with ﬂuorocarbon.
The measurement preserved ultrasensitivity, with an LOD of 6
fM (Figure 4B). We used this measurement to determine the
endogenous concentration of TNF-α in pooled human serum,
which is below the detection limit of a conventional ELISA.14
The measured concentration was 0.031 ± 0.001 pM in 25%
serum (Figure 4B), which translates to 0.125± 0.004 pM in pure
serum. This value is consistent with those determined previously
using other single-molecule approaches.4a,15 At higher concen-
trations, using a low threshold of 0.11 positive fraction (Figure
4C) provided a dynamic range of ∼103, and using a high
threshold of 0.8 positive fraction (Figure 4D) extended it to 2
nM, for a total dynamic range of ∼300,000-fold. While this is
wider than the dynamic range achieved previously by digital
readout alone (∼316-fold)3c or the digital and analog readouts
combined (∼13,000-fold),7 it is smaller than the dynamic range
obtained under the more ideal conditions with enzymes (Figure
3).
We conclude that the concept of Brownian trapping with drift
can be used for digital measurements of proteins that combine
high sensitivity of digital assays with large dynamic range of
qPCR but with an end-point readout. This combination of
features has not been demonstrated previously and may be
advantageous even for nucleic acid quantiﬁcation. These ﬁndings
justify performing future work to understand how combinations
Figure 3. Experimental evaluation of the digital protein measurement
with Brownian trapping with drift. (A) Capture curves of biotinylated β-
galactosidase with concentrations ranging from 10 aM to 0.3 nM. The
red lines indicate data replotted in panels B, C, and D. (B) A plot of the
positive fraction of beads at the ﬁrst region vs low analyte
concentrations, from 9 aM to 20 fM. The dotted horizontal line
represents the lower limit of quantiﬁcation. (C) A plot of Rq (region of
quantiﬁcation, threshold of 0.07 positive fraction) vs the logarithm of
analyte concentration ranging from 1 fM to 1 pM. (D) A plot of Rq
(threshold of 0.8 positive fraction) vs the logarithm of analyte
concentration ranging from 0.1 pM to 0.3 nM. (E) A plot of the
positive fraction of beads in the entire array in a standard digital protein
assay at concentrations ranging from 0.1 fM to 10 nM. The dotted
horizontal lines represent the upper and lower limits of quantiﬁcation.
Figure 4.Test of digital measurements based on Brownian trapping with
advective drift using human TNF-α. (A) Capture curves obtained from
25% bovine serum samples spiked with increasing concentrations of
recombinant TNF-α. From bottom to top, curves represent TNF-α
concentrations of 0, 0.01, 0.02, 0.1, 1, 10, 100, 1000, and 2000 pM. The
blue line underlines the background signal level directly measured in the
assays at low concentrations. (B) A plot of positive bead fraction at low
concentration of TNF-α corresponding to the vertical dotted red line in
A. The dotted horizontal line represents the background signal + 3SD.
The endogenous [TNF-α] in 25% pooled human serum is shown by the
star symbol. (C) A plot of Rq (region of quantiﬁcation, threshold of 0.11
positive fraction) vs the logarithm of TNF-α concentration ranging from
20 fM to 10 pM. (D) A plot of Rq (threshold of 0.8 positive fraction) vs
the logarithm of TNF-α concentration ranging from 1 pM to 2 nM.
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of values (and their variability) of Pex, Pez, Da, capture eﬃciency,
ﬂow control,16 device design, and assay chemistry impact assay
performance and enable the design of optimal assays for a given
analyte. For example, given the similarity to qPCR, we anticipate
lower resolution at higher concentrations where errors in
determining the Rq parameter would lead to exponentially
larger errors in quantiﬁcation. It remains to be tested whether
methods analogous to those used in qPCR (e.g., the use of spatial
or color multiplexing to introduce quantiﬁcation controls and/or
introduce parallel assays targeting multiple epitopes of the same
target) could be used with this approach. The low sample
consumption and the use of smaller numbers of wells per
measurement with a given dynamic range (see Supporting
Information S8) would make this approach compatible with
spatial multiplexing and single-cell analysis.17 Finally, we
emphasize that at low concentrations of analyte the downstream
regions provide a direct measurement of the background signal of
the assay (Figure 4A). This feature should be useful to improve
assay ﬁdelity.
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